Uncomplicated gonorrhea is extremely frequent in Rwanda. The official notifications, varying between 6,000 and 15,000 cases yearly for a population of about 5 million people (5) , largely underestimate the reality. Penicillinaseproducing Neisseria gonorrhoeae emerged late in 1982 and reached 40% of all isolates during 1984. High-level resistance to penicillin in non-penicillinase producing N. gonorrhoeae is also common (J. Bogaerts, J. Vandepitte, E. Van Dijck, R. Van Hoof, and P. Piot, Genitourin. Med., in press).
Therefore, alternative and, if possible, low-cost treatment regimens are needed that will be effective against such isolates and that can be administered as a single-dose therapy. Thiamphenicol is inexpensive and can be given as a single oral dose. Much research has been done on its toxicity and efficacy in the treatment of uncomplicated gonorrhea (11) , with failures being correlated with MICs of -1 ,ug/ml (4, 6, 8, 12) .
Norfloxacin, a new orally administered quinolone, seems to be a very promising agent in the treatment of gonorrhea. It shows very high in vitro activity against N. gonorrhoeae (3, 9) and has been used with success in uncomplicated gonorrhea (1) , like other newer quinolones (2, 6, 7, 10) . In vitro resistance to this group of antibiotics has not been reported until now.
The aim of this study was to compare two single-dose regimens for the treatment of uncomplicated gonorrhea: norfloxacin (800 mg) and thiamphenicol (2.5 g). and 108 (79 male, 29 female) were treated with norfloxacin. Only patients from whom N. gonorrhoeae was isolated during the first visit and who returned for the control culture 2 to 5 days after treatment were considered as evaluable. All patients except one were Rwandese, and both treatment groups were similar with respect to age, body weight, and duration of symptoms.
MATERIALS AND METHODS
The thiamphenicol treatment regimen was stopped when it became clear that the failure rate was unacceptably high. Another group of patients (78 males, 2 females), who were selected based on the same selection criteria described above, were treated with norfloxacin alone during December
1985.
Treatment regimens and evaluation. All patients were treated with single oral doses of 800 mg of norfloxacin or 2.5 g of thiamphenicol, which were administered by one of the investigators. Patients were instructed to abstain from sexual contact before the control culture. Classification of cure or failure was based on the result of the culture for N. gonorrhoeae at the follow-up visit. The chi-square test with the Yates correction and the Fisher exact test were used for statistical analyses. Tolerance and acceptability of the drug regimens was evaluated by interrogating patients specifically about nausea, vomiting, and headaches during the day of treatment, because there were no spontaneous complaints.
Assays for norfloxacin in serum. Concentrations of norfloxacin in serum were determined by an agar well method in antibiotic medium no. 2 (Oxoid Ltd., London, England) adjusted to pH 7.8 with 1 N NaOH. Enterobacter cloacae ATCC 23355 was used as the test organism. The reliable lower limit of detection was 0.5 ,ug/ml, and the coefficient of variation was 5.6%. Blood samples were taken 1 h after administration of 800 mg of norfloxacin in 35 patients and 90 min after administration in 38 MICs were determined on the surviving strains by an agar dilution method on diagnostic sensitivity test agar (Oxoid) supplemented with 1% IsoVitaleX (BBL Microbiology Systems, Cockeysville, Md.) and 2% hemoglobin. The inoculum, corresponding to 105 CFU per spot, was delivered with a multipoint inoculator. Cultures were incubated for 24 h at 37°C in a 5% CO2 atmosphere. The MIC was read as the lowest concentration of the antimicrobial agent that allowed no visible growth.
RESULTS
Because the second group of patients treated with norfloxacin was selected on the same criteria as in the comparative study, the results were pooled. A total of 263 patients were enrolled in the study: 188 (37 women, 151 men) received norfloxacin and 75 (8 women, 67 men) received thiamphenicol. Evaluable data were obtained from 122 patients (18 women, 104 men) in the norfloxacin group and 46 (2 women, 44 men) in the thiamphenicol group. In the norfloxacin group, 119 (97.5%) patients were cured as opposed to only 35 (76.0%) cures in the thiamphenicol group. Treatment failures were treated and cured subsequently with 2 g of spectinomycin administered intramuscularly. With both regimens all women were cured. In Table 1 background data and the results of the study are summarized.
Clinical symptoms of urethritis persisted in the 11 men in whom thiamphenicol treatment failed. Surprisingly, in the three patients showing a positive control culture (with scanty growth) after norfloxacin treatment, no secretions nor clinical signs of urethritis nor subjective complaints were observed. The positive test-of-cure cultures in these three patients were probably not due to reinfection because they reported for a control culture on the second day after the drug was administered; however, reinfection cannot be ruled out with certainty.
The correlation between clinical outcome and in vitro susceptibility to thiamphenicol in 23 patients are shown in Table 2 . The MICs of thiamphenicol for pretreatment iso- 3 7 a Seven patients had both pre-and posttreatment isolates for susceptibility testing; three patients had only pretreatment isolates. lates were determined in these patients. In 7 of the 10 treatment failures the MIC of thiamphenicol for the posttreatment isolates was also determined. Pretreatment isolates from patients in whom thiamphenicol treatment failed were not significantly less suceptible (MIC, 1 ,ug/ml) than the isolates from the patients that were successfully treated (Fisher exact test, P = 0.228), but the seven posttreatment isolates uniformly showed a MIC of 1 ,g of thiamphenicol per ml. One patient in the failure group had a penicillinaseproducing N. gonorrhoeae isolate in the first culture and a penicillinase-negative, high-level resistant strain (MIC for penicillin, 2 p.g/ml) in the control culture. To control absorption a single blood sample was taken after administration of 800 mg of norfloxacin in one set of patients after 60 min and in another set of patients after 90 min. Measurable levels in serum ranging from 0.5 to 2.6 mg/liter (mean, 1.57 mg/liter) were present in 22 of 35 patients after 60 min, and levels in serum from 0.5 to 3.8 mg/liter (mean, 1.74 mg/liter) were observed in 32 of 38 patients with samples taken 90 min after administration. All patients with levels in serum below 0.5 mg/liter (limit of reliability) were nevertheless cured. The three patients that did not respond to norfloxacin treatment showed levels in serum after 90 min of 1.9, 2.0, and 2.6 p.g/ml. Of these three patients only one pretreatment isolate (MIC, 0.06 ,ug/ml) and no posttreatment isolates were available for susceptibility testing. Penicillinase-producing N. gonorrhoeae isolates were common in both the norfloxacin (41.8%) and in the thiamphenicol (32.6%) treatment regimens. No differences existed between patients of both treatment regimens with regard to body weight ( Table 1) . The rates of postgonococcal urethritis in men, as defined by the presence of a serous, culture-negative urethral discharge after treatment, were 24.8% (25 of 101) in the norfloxacin group and 15.2% (5 of 33) in the thiamphenicol group (X2 = 0.97; P > 0.05). This difference was not statistically significant.
Norfloxacin and thiamphenicol were well tolerated, and no side effects were noted in these patients.
The MICs for 63 pretreatment strains isolated in this study are shown in Table 3 . The high percentage of strains with decreased susceptibility (MIC, 0.06 to 0.25 p.g/ml) or resistance to penicillin G in the non-penicillinase-producing N. gonorrhoeae strains, the excellent activity of norfloxacin, and the large number of strains that were only inhibited by 1 ,ug of thiamphenicol per ml are shown. A total of 70% of the penicillinase-producing N. gonorrhoeae strains and 80% of the non-penicillinase-producing N. gonorrhoeae strains that were resistant were only borderline susceptible to tetracycline (MIC, .2 ,ug/ml). All strains were susceptible to kanamycin and spectinomycin. 
